Table 1.

Patient demographics

Patient	Skeletal AE	Age	Sex	Race	BMI	Tumor type and stage	Treatment Regimen	Bone Metastases?	Other irAEs
1	Compression fractures of T6, T7, T10, T11, and T12; rib and pelvic fractures	75	M	C	19	Melanoma Stage IV	Pembrolizumab	No	None
2	Compression fractures, T6–12, L1	52	M	C	27	Melanoma Stage IV	Nivolumab	Yes	None
3	Compression fracture, T11; lumbar osteomalacia	58	M	C	29	Melanoma Stage IV	Pembrolizumab	No	None
4	Resorptive bone lesion, left shoulder	60	M	C	24	Melanoma Stage IV	Ipilimumab/nivolumab	No	Pneumonitis, hypophysitis, inflammatory arthritis
5	Resorptive bone lesion, right wrist	60	F	C	26	Renal cell carcinoma Stage IV	Nivolumab	Yes	Inflammatory arthritis
6	Resorptive bone lesion, right clavicle	51	M	C	25	Non small cell lung cancer Stage II	Ipilimumab/nivolumab	Yes	Inflammatory arthritis

(AE) Adverse event, (irAEs) Immune-related adverse events